Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers

BACKGROUND: Aberrant progesterone/receptor activator of nuclear factor κβ (RANK) signaling has been implicated in BRCA1 breast cancer development. Furthermore, lower circulating RANKL has been reported among women with a BRCA mutation compared to non-carriers; however, there have been no reports of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaman, Tasnim, Sun, Ping, Narod, Steven A., Salmena, Leonardo, Kotsopoulos, Joanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497430/
https://www.ncbi.nlm.nih.gov/pubmed/31069010
http://dx.doi.org/10.18632/oncotarget.26810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497430/
https://www.ncbi.nlm.nih.gov/pubmed/31069010
http://dx.doi.org/10.18632/oncotarget.26810

Ejemplares similares